查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1924716

核子醫學和放射性藥物市場（按產品類型、同位素類型、應用、最終用戶和分銷管道分類）—2026-2032年全球預測

Nuclear Medicine & Radiopharmaceuticals Market by Product Type, Isotope Type, Application, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 194 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，核醫和放射性藥物市場價值將達到 95.2 億美元，到 2026 年將成長至 100.7 億美元，到 2032 年將達到 151.2 億美元，年複合成長率為 6.83%。

關鍵市場統計數據
基準年 2025 95.2億美元
預計年份：2026年 100.7億美元
預測年份 2032 151.2億美元
複合年成長率 (%) 6.83%

本書權威地介紹了影響現代核子醫學和放射性藥物的技術、監管和供應鏈因素。

核子醫學和放射性藥物領域正處於快速科學創新和日益複雜的商業性趨勢的交匯點。分子影像示蹤劑、標靶放射性治療藥物和生產技術的進步，與臨床上對精準診斷和個人化治療方案日益成長的重視相輔相成。本文概述了日趨成熟的技術、日益嚴格的監管以及不斷演變的供應鏈結構如何影響工業界、臨床和研究相關人員的策略選擇。

對臨床、製造和監管變革融合的全面分析，這些變革將加速精準診斷和放射治療策略的發展。

核子醫學和放射性藥物領域正經歷多重變革，這些變革涵蓋臨床實踐、生產製造和政策等多個方面，並正在重新定義。在臨床方面，精準診斷和治療診斷學的趨勢正在加速分子特異性示蹤劑和標靶放射性核種療法的應用，促進影像專家、腫瘤學家和核醫學團隊之間的合作。隨著研發人員優先開發兼具診斷和治療功能的示蹤劑，這種臨床發展趨勢正在重塑研究重點和商業化進程。

深入評估2025年關稅如何重塑放射性藥物產業的供應鏈韌性、籌資策略和採購行為。

2025年對放射性藥物原料及相關醫用同位素組件徵收的關稅對價值鏈、採購慣例和終端用戶成本產生了多方面的影響，但並未改變診斷和治療藥物本身的臨床價值。這項關稅政策提高了對本地生產的重視程度，促使一些機構和生產商重新評估其迴旋加速器設備、產生器系統、前驅化學品和屏蔽組件的籌資策略。這種轉變有利於那些擁有現有國內生產能力的相關人員，並鼓勵對鄰近區域合作夥伴和契約製造安排進行投資。

詳細的細分框架，重點介紹產品類型、臨床應用、最終用戶概況、通路和同位素生產方法，以指南策略規劃。

市場區隔分析提供了一個結構化的視角，幫助我們了解哪些治療和診斷途徑正在推動臨床應用，以及哪些領域的生產投資最為有效。市場依產品類型分析，診斷和治療放射性藥物是兩大主要類別。診斷放射性藥物進一步細分為PET和SPECT放射性藥物，其中PET放射性藥物又分為F-18和Ga-68放射性藥物，SPECT放射性藥物則分為非Tc-99m放射性藥物和Tc-99m放射性藥物。治療放射性藥物進一步分為α粒子放射性藥物和BETA粒子放射性藥物。 α粒子放射性藥物包括Ra-223療法，而BETA粒子放射性藥物包括I-131、Lu-177和Y-90療法。

區域分析突顯了美洲、歐洲、中東和非洲以及亞太地區在基礎設施、法規環境和採用趨勢方面的差異。

區域趨勢在放射性藥物的應用、生產和分銷中發揮關鍵作用，每個區域都面臨獨特的機會和挑戰。在美洲，PET成像技術的成熟臨床應用和對放射性藥物日益成長的投資，加上密集的醫療中心和研究機構網路，為先進的示踪劑測試和本地迴旋加速器的建設提供了支持。透過區域製造地和策略夥伴關係來降低跨境差異，供應鏈的韌性日益受到重視。

對公司能力、夥伴關係模式和生產優勢進行策略評估，以確定其競爭地位和長期生存能力。

核醫和放射性藥物產業的公司層級發展趨勢反映了一系列策略性舉措，涵蓋垂直整合和專業服務等。主要企業正投資於示踪劑開發、迴旋加速器或發生器供應、放射化學專業知識以及臨床分銷服務的一體化能力，以確保品管並縮短患者用藥時間。其他企業則專注於自身優勢的細分領域，例如新型放射性核種發現、自動化放射化學模組和契約製造，以滿足日益成長的學術和商業研發客戶的需求。

為產業領導者提供實用建議，以協調供應鏈彈性、監管規劃、臨床整合和可擴展生產。

產業領導者若想掌握核醫和放射性藥物領域的成長勢頭，應採取切實可行的綜合性優先事項，兼顧臨床價值和營運韌性。首先，應透過投資雙源策略來加強供應鏈多元化，該策略將區域迴旋加速器設施和發生器供應網路結合，以降低單點故障和關稅帶來的中斷風險​​。其次，應透過生產能夠滿足不同司法管轄區要求的材料，並優先考慮協調一致的監管溝通，來簡化核准流程並促進國際臨床計畫。

採用透明嚴謹的調查方法，結合專家訪談、權威二手資料和跨領域分析架構。

我們的研究途徑融合了第一手和第二手調查方法，以確保對核醫和放射性藥物領域獲得嚴謹且多角度的洞察。第一手研究包括對臨床醫生、放射性藥物藥劑師、供應鏈管理人員和監管專家進行結構化訪談，以了解現場操作挑戰和應用促進因素。此外，我們還與製造商、合約服務供應商和分銷合作夥伴進行了討論，以補充這些專家見解，從而揭示影響示踪劑供應和臨床工作流程的商業性和物流因素。

簡明扼要地總結了臨床進展、生產方案、區域差異以及生態系統內各相關人員的策略重點。

本執行摘要指出，在臨床創新、不斷發展的生產技術以及不斷變化的貿易和監管環境的推動下，核醫學和放射性藥物行業正處於轉折點。診斷和治療放射性藥物正日益融入病患診療流程。 PET 和 SPECT 追蹤劑正在改善疾病的表徵，而標靶放射療法則為難治性疾病提供了新的治療選擇。迴旋加速器生產的同位素與基於發生器的系統之間的生產方法選擇，對藥物的取得、物流和資金配置決策有重大影響。

目錄

第1章：序言

第2章調查方法

  • 研究設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查前提
  • 調查限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會地圖
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：核子醫學和放射性藥物市場（按產品類型分類）

  • 診斷用放射性藥物
    • PET放射性藥物
      • F-18放射性藥物
      • Ga-68放射性藥物
    • SPECT放射性藥物
      • 非Tc-99m放射性藥物
      • 锝-99m放射性藥物
  • 治療性放射性藥物
    • α粒子放射性藥物
    • BETA射線放射性藥物
      • 碘-131 (I-131)治療方法
      • 基於釕-177 (Lu-177) 的治療方法
      • 基於Y-90的治療方法

9. 按同位素類型分類的核子醫學和放射性藥物市場

  • 迴旋加速器產生的同位素
    • C-11
    • F-18
  • 基於發生器的同位素
    • Ge-68 Ga-68 發電機
    • Mo-99 Tc-99m 產生器

第10章 核子醫學和放射性藥物市場（按應用領域分類）

  • 骨骼影像
  • 心臟病學
  • 發炎成像
  • 神經病學
  • 腫瘤學

第11章 核子醫學和放射性藥物市場（按最終用戶分類）

  • 門診護理設施
  • 診斷影像中心
  • 醫院放射科
  • 研究所

第12章 核子醫學和放射性藥物市場（按分銷管道分類）

  • 離線
  • 線上

第13章 核醫與放射性藥物市場（按地區分類）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章 核醫與放射性藥物市場（依組別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 各國核子醫學與放射性藥物市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章：美國核子醫學與放射性藥物市場

第17章 中國核醫與放射性藥物市場

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Advanced Accelerator Applications SA
  • AstraZeneca PLC
  • Bayer AG
  • Bracco Imaging SpA
  • Bristol-Myers Squibb Company
  • BWX Technologies, Inc.
  • Cardinal Health, Inc.
  • Clarity Pharmaceuticals Ltd.
  • Curium Pharma
  • Eckert & Ziegler SE
  • Eli Lilly and Company
  • GE HealthCare Technologies Inc.
  • Ion Beam Applications SA
  • ITM Isotope Technologies Munich SE
  • Jubilant Pharmova Limited
  • Lantheus Holdings, Inc.
  • NorthStar Medical Radioisotopes, LLC
  • Novartis AG
  • Siemens Healthineers AG
  • Telix Pharmaceuticals Limited
Product Code: MRR-7A380DA7C449

The Nuclear Medicine & Radiopharmaceuticals Market was valued at USD 9.52 billion in 2025 and is projected to grow to USD 10.07 billion in 2026, with a CAGR of 6.83%, reaching USD 15.12 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 9.52 billion
Estimated Year [2026] USD 10.07 billion
Forecast Year [2032] USD 15.12 billion
CAGR (%) 6.83%

An authoritative introduction that contextualizes technological, regulatory, and supply chain forces shaping contemporary nuclear medicine and radiopharmaceuticals

The landscape of nuclear medicine and radiopharmaceuticals stands at the intersection of rapid scientific innovation and increasingly complex commercial dynamics. Advances in molecular imaging tracers, targeted radiotherapeutics, and production technologies have converged with a heightened clinical emphasis on precision diagnostics and personalized treatment pathways. This introduction sets the stage for how technological maturation, tighter regulatory scrutiny, and evolving supply chain architectures are influencing strategic choices across industry, clinical, and research stakeholders.

Diagnostic radiopharmaceuticals continue to expand their clinical reach as PET and SPECT tracers deliver higher-resolution disease characterization, while therapeutic radiopharmaceuticals are gaining traction for targeted oncology indications where conventional modalities have limitations. Concurrently, production paradigms that include cyclotron-produced isotopes and generator-based supply chains are recalibrating site-of-care logistics and vendor relationships. Regulatory frameworks are adapting to novel radiopharmaceutical modalities, balancing expedited patient access with stringent safety and manufacturing quality expectations.

As stakeholders navigate this evolving ecosystem, an integrated perspective that considers clinical utility, manufacturing resilience, regulatory pathways, and commercial scalability is essential. This introduction provides a framework for the sections that follow, focusing on transformative market shifts, tariff-driven trade implications, segmentation-based insights, and regionally differentiated strategies that together inform high-impact decision-making.

A comprehensive analysis of converging clinical, manufacturing, and regulatory shifts that are accelerating precision diagnostics and radiotherapeutic strategies

Several transformative shifts are redefining nuclear medicine and radiopharmaceuticals, and they operate across clinical practice, manufacturing, and policy domains. Clinically, the move toward precision diagnostics and theranostics is accelerating adoption of molecularly specific tracers and targeted radionuclide therapies, driving collaborations between imaging specialists, oncologists, and nuclear medicine teams. This clinical momentum is in turn shaping research priorities and commercial pipelines as developers prioritize tracers that enable both diagnosis and therapy pairing.

On the manufacturing front, decentralization is gaining traction; hospitals and regional centers are investing in on-site cyclotrons and radiochemistry suites to reduce lead times for short-lived isotopes while also forming partnerships with contract manufacturing organizations for complex radiotherapeutics. Generator-based supply chains remain critical for broader accessibility, particularly in settings where cyclotron infrastructure is impractical. Regulatory evolution is another inflection point, with agencies working to harmonize quality expectations for novel radionuclides and streamline pathways that maintain safety without unduly delaying patient access.

Finally, the commercial landscape is experiencing strategic consolidation and cross-sector partnerships that bring radiochemistry expertise, supply chain scale, and clinical distribution networks together. These shifts are not isolated; rather, they compound one another, creating an environment in which nimble organizations that align clinical value, manufacturing reliability, and regulatory foresight will capture the greatest strategic advantage.

A nuanced evaluation of how 2025 tariff measures reshaped supply chain resilience, sourcing strategies, and procurement behaviors across the radiopharmaceutical sector

The introduction of tariffs affecting radiopharmaceutical inputs and related medical isotope components in 2025 created layered effects across supply chains, procurement practices, and end-user costs without altering the underlying clinical value of diagnostic and therapeutic agents. Tariff policy increased the operational emphasis on localized production, prompting some institutions and producers to reassess sourcing strategies for cyclotron equipment, generator systems, precursor chemicals, and shielding components. This reorientation favored stakeholders with existing domestic manufacturing capabilities and incentivized investments in near-shore partners and contract manufacturing arrangements.

Procurement teams responded by diversifying supplier portfolios and negotiating long-term agreements that absorb tariff volatility, while clinical operations implemented tighter inventory management for short-lived isotopes to mitigate disruptions. The indirect cost effects were felt across distribution channels, with direct-sales models gaining attractiveness for large institutional buyers seeking single-vendor accountability and bundled service agreements that reduce administrative complexity. At the same time, smaller diagnostic centers and research organizations relied more heavily on regional distributors and generator-based isotopes to preserve clinical continuity.

Policy uncertainty also accelerated conversations on regulatory and trade harmonization for medical isotopes, as stakeholders recognized that predictable cross-border flows are essential for maintaining access to specialized tracers. In sum, tariffs acted as a catalyst for supply chain resilience investments and strategic sourcing decisions that will influence procurement and operational models going forward.

An in-depth segmentation framework that delineates product types, clinical applications, end-user profiles, channels, and isotope production modalities to guide strategy

Segmentation analysis provides a structured lens to understand which therapeutic and diagnostic pathways are driving clinical adoption and where manufacturing investments are most productive. The market is studied across Product Type with Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals as primary categories; Diagnostic Radiopharmaceuticals further differentiate into PET Radiopharmaceuticals and SPECT Radiopharmaceuticals, where PET subdivides into F-18 Radiopharmaceuticals and Ga-68 Radiopharmaceuticals, and SPECT separates into Non Tc-99m Radiopharmaceuticals and Tc-99m Radiopharmaceuticals. Therapeutic Radiopharmaceuticals are further parsed into Alpha Emitting Radiopharmaceuticals and Beta Emitting Radiopharmaceuticals, with Alpha Emitting Radiopharmaceuticals including Ra-223 Therapies and Beta Emitting Radiopharmaceuticals encompassing I-131 Based Therapies, Lu-177 Based Therapies, and Y-90 Based Therapies.

When viewed by Application, the analysis considers Bone Imaging, Cardiology, Inflammation Imaging, Neurology, and Oncology, unpacking clinical adoption drivers and reimbursement dynamics unique to each therapeutic area. End User segmentation examines Ambulatory Care Facilities, Diagnostic Imaging Centers, Hospital Radiology Departments, and Research Organizations, which differ in capital intensity, in-house radiochemistry capacity, and procurement sophistication. Distribution Channel segmentation contrasts Direct Sales, Indirect Sales, and Online Channels to reveal where integrated service models or distributor networks provide competitive advantage. Finally, Isotope Type segmentation highlights the operational distinctions between Cyclotron Produced Isotopes and Generator Based Isotopes, with cyclotron-produced isotopes further identified as C-11 and F-18 and generator-based isotopes described through Ge-68 Ga-68 Generators and Mo-99 Tc-99m Generators, underscoring how production technology influences logistics, tracer half-life management, and access across clinical settings.

Taken together, these segmentation layers illuminate which product-development priorities, production investments, and commercial channels align with clinical needs and operational realities, providing a roadmap for targeted strategy and resource allocation.

A regional analysis revealing differentiated infrastructure, regulatory environments, and adoption trajectories across Americas, Europe, Middle East & Africa, and Asia-Pacific

Regional dynamics play a pivotal role in shaping the adoption, production, and distribution of radiopharmaceuticals, and each geography presents distinct opportunities and constraints. In the Americas, established clinical adoption of PET imaging and growing investment in radiotherapeutics coincide with a dense network of tertiary care centers and research institutions, supporting advanced tracer trials and on-site cyclotron installations. Supply chain resilience is increasingly addressed through regional manufacturing hubs and strategic partnerships to mitigate cross-border volatility.

Europe, Middle East & Africa features heterogeneous regulatory environments and infrastructure maturity, where leading healthcare systems support advanced theranostic programs while many regions rely on generator-based isotopes to expand access in lower-capacity settings. Collaboration across national regulatory authorities and pan-regional networks is instrumental for harmonizing quality standards and enabling cross-border clinical trials. In the Asia-Pacific region, robust capital investment, accelerated adoption of new imaging technologies, and large patient populations are driving rapid clinical uptake, while significant public and private investment in cyclotron infrastructure and radiopharmacy capacity is expanding local production capabilities.

Across all regions, local policy, reimbursement frameworks, and clinical guidelines materially influence which isotopes and modalities gain traction. Stakeholders should therefore craft region-specific strategies that align production investments, regulatory engagement, and distribution models with the distinct clinical and infrastructure profiles of each geography.

A strategic appraisal of company capabilities, partnership models, and production strengths that determine competitive positioning and long-term viability

Company-level dynamics within nuclear medicine and radiopharmaceuticals reflect a broad array of strategic approaches, ranging from vertical integration to specialized service provision. Leading organizations are investing in integrated capabilities that combine tracer development, cyclotron or generator supply, radiochemistry expertise, and clinical distribution services to control quality and shorten time-to-patient. Others are focusing on niche strengths such as novel radionuclide discovery, automated radiochemistry modules, or contract manufacturing to serve a growing base of academic and commercial developers.

Partnerships between pharmaceutical developers, imaging device manufacturers, and clinical networks are increasingly common as stakeholders seek to align tracer innovation with clinical validation pathways and reimbursement strategies. Companies that can demonstrate robust manufacturing quality systems, validated cold-chain logistics, and scalable radiopharmacy operations command strategic advantage when negotiating supply agreements with large hospital systems and imaging networks. At the same time, smaller agile firms are capitalizing on early-stage collaboration opportunities with academic centers to advance novel tracers through proof-of-concept studies.

Competitive differentiation often hinges on the ability to secure reliable isotope supply, demonstrate regulatory compliance across jurisdictions, and support customers with turnkey services spanning authorization, logistics, and clinical trial support. For investors and partners, assessing a company's depth in production technology, regulatory expertise, and clinical engagement offers a pragmatic lens into its long-term viability and strategic fit.

A pragmatic set of actionable recommendations that align supply resilience, regulatory planning, clinical integration, and scalable manufacturing for industry leaders

Industry leaders seeking to capitalize on the momentum in nuclear medicine and radiopharmaceuticals should pursue a set of actionable, integrated priorities that balance clinical value with operational resiliency. First, strengthen supply chain diversification by investing in dual-source strategies that combine local cyclotron capacity with regional generator networks to mitigate single-point failures and tariff-induced disruptions. Second, prioritize harmonized regulatory engagement by building dossiers that anticipate cross-jurisdictional requirements, enabling smoother approvals and facilitating international clinical programs.

Third, accelerate clinical integration by partnering with hospitals and specialist centers to co-develop tracer pathways and to generate real-world evidence that supports reimbursement dialogues. Fourth, adopt scalable manufacturing platforms and validated quality systems that enable rapid scale-up of promising radiotherapeutics while maintaining compliance and traceability. Fifth, enhance commercial models by offering bundled service agreements-combining supply, onsite training, and logistics-to reduce friction for institutional buyers and to differentiate from commodity suppliers.

Finally, invest in workforce development and radiopharmacy training to ensure that facilities adopting advanced tracers have competent staff to manage complex radiochemical preparations and safety protocols. Taken together, these recommendations create a roadmap for organizations to deliver clinical impact while building resilient, growth-ready operations.

A transparent and rigorous research methodology combining expert primary interviews, authoritative secondary sources, and cross-segmentation analytical frameworks

The research approach integrates primary and secondary methods designed to ensure rigorous, triangulated insights into nuclear medicine and radiopharmaceuticals. Primary research included structured interviews with clinicians, radiopharmacists, supply chain managers, and regulatory specialists to capture frontline operational challenges and adoption drivers. These expert perspectives were complemented by discussions with manufacturers, contract service providers, and distribution partners to surface commercial and logistics considerations that influence tracer availability and clinical workflows.

Secondary research drew on peer-reviewed literature, regulatory guidance documents, clinical trial registries, and publicly available technical standards to ground findings in validated scientific and policy sources. Data synthesis employed cross-segmentation analysis to map Product Type, Application, End User, Distribution Channel, and Isotope Type against regional infrastructure and regulatory realities. Analytical rigor was ensured through methodical cross-checking of interview insights with publicly documented approvals, manufacturing practices, and clinical guidelines.

Where appropriate, sensitivity analysis was applied to assess operational risk drivers such as isotope half-life constraints, cold-chain logistics, and dependency on specialized precursor materials. Together, these methodological elements enable a robust understanding of both the clinical and commercial levers that shape strategy and investment decisions in the sector.

A concise conclusion synthesizing clinical advances, production choices, regional differentiation, and strategic priorities for stakeholders across the ecosystem

This executive synthesis underscores that nuclear medicine and radiopharmaceuticals are at an inflection point driven by clinical innovation, production technology evolution, and evolving trade and regulatory landscapes. Diagnostic and therapeutic radiopharmaceuticals are increasingly integrated into patient care pathways, with PET and SPECT tracers improving disease characterization and targeted radiotherapies offering alternative options for difficult-to-treat conditions. Production modality choices between cyclotron-produced isotopes and generator-based systems materially influence access, logistics, and capital allocation decisions.

Supply chain resilience, shaped by recent tariff dynamics and broader geopolitical considerations, is now a core strategic imperative. Organizations that proactively align manufacturing capabilities, regulatory engagement, and clinical partnerships will be best positioned to translate scientific promise into clinical impact. Regional differentiation further underscores the need for tailored approaches that respect local infrastructure, reimbursement environments, and regulatory expectations. Collectively, these insights provide a practical foundation for leaders to make informed decisions about product development priorities, manufacturing investments, and commercial partnerships as the field continues to advance.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Nuclear Medicine & Radiopharmaceuticals Market, by Product Type

  • 8.1. Diagnostic Radiopharmaceuticals
    • 8.1.1. PET Radiopharmaceuticals
      • 8.1.1.1. F-18 Radiopharmaceuticals
      • 8.1.1.2. Ga-68 Radiopharmaceuticals
    • 8.1.2. SPECT Radiopharmaceuticals
      • 8.1.2.1. Non Tc-99m Radiopharmaceuticals
      • 8.1.2.2. Tc-99m Radiopharmaceuticals
  • 8.2. Therapeutic Radiopharmaceuticals
    • 8.2.1. Alpha Emitting Radiopharmaceuticals
    • 8.2.2. Beta Emitting Radiopharmaceuticals
      • 8.2.2.1. I-131 Based Therapies
      • 8.2.2.2. Lu-177 Based Therapies
      • 8.2.2.3. Y-90 Based Therapies

9. Nuclear Medicine & Radiopharmaceuticals Market, by Isotope Type

  • 9.1. Cyclotron Produced Isotopes
    • 9.1.1. C-11
    • 9.1.2. F-18
  • 9.2. Generator Based Isotopes
    • 9.2.1. Ge-68 Ga-68 Generators
    • 9.2.2. Mo-99 Tc-99m Generators

10. Nuclear Medicine & Radiopharmaceuticals Market, by Application

  • 10.1. Bone Imaging
  • 10.2. Cardiology
  • 10.3. Inflammation Imaging
  • 10.4. Neurology
  • 10.5. Oncology

11. Nuclear Medicine & Radiopharmaceuticals Market, by End User

  • 11.1. Ambulatory Care Facilities
  • 11.2. Diagnostic Imaging Centers
  • 11.3. Hospital Radiology Departments
  • 11.4. Research Organizations

12. Nuclear Medicine & Radiopharmaceuticals Market, by Distribution Channel

  • 12.1. Offline
  • 12.2. Online

13. Nuclear Medicine & Radiopharmaceuticals Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Nuclear Medicine & Radiopharmaceuticals Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Nuclear Medicine & Radiopharmaceuticals Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Nuclear Medicine & Radiopharmaceuticals Market

17. China Nuclear Medicine & Radiopharmaceuticals Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Advanced Accelerator Applications S.A.
  • 18.6. AstraZeneca PLC
  • 18.7. Bayer AG
  • 18.8. Bracco Imaging S.p.A.
  • 18.9. Bristol-Myers Squibb Company
  • 18.10. BWX Technologies, Inc.
  • 18.11. Cardinal Health, Inc.
  • 18.12. Clarity Pharmaceuticals Ltd.
  • 18.13. Curium Pharma
  • 18.14. Eckert & Ziegler SE
  • 18.15. Eli Lilly and Company
  • 18.16. GE HealthCare Technologies Inc.
  • 18.17. Ion Beam Applications S.A.
  • 18.18. ITM Isotope Technologies Munich SE
  • 18.19. Jubilant Pharmova Limited
  • 18.20. Lantheus Holdings, Inc.
  • 18.21. NorthStar Medical Radioisotopes, LLC
  • 18.22. Novartis AG
  • 18.23. Siemens Healthineers AG
  • 18.24. Telix Pharmaceuticals Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY ISOTOPE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY DIAGNOSTIC RADIOPHARMACEUTICALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY DIAGNOSTIC RADIOPHARMACEUTICALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY DIAGNOSTIC RADIOPHARMACEUTICALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY DIAGNOSTIC RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY PET RADIOPHARMACEUTICALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY PET RADIOPHARMACEUTICALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY PET RADIOPHARMACEUTICALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY PET RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY F-18 RADIOPHARMACEUTICALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY F-18 RADIOPHARMACEUTICALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY F-18 RADIOPHARMACEUTICALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY GA-68 RADIOPHARMACEUTICALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY GA-68 RADIOPHARMACEUTICALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY GA-68 RADIOPHARMACEUTICALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY SPECT RADIOPHARMACEUTICALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY SPECT RADIOPHARMACEUTICALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY SPECT RADIOPHARMACEUTICALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY SPECT RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY NON TC-99M RADIOPHARMACEUTICALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY NON TC-99M RADIOPHARMACEUTICALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY NON TC-99M RADIOPHARMACEUTICALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY TC-99M RADIOPHARMACEUTICALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY TC-99M RADIOPHARMACEUTICALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY TC-99M RADIOPHARMACEUTICALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC RADIOPHARMACEUTICALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC RADIOPHARMACEUTICALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC RADIOPHARMACEUTICALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY ALPHA EMITTING RADIOPHARMACEUTICALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY ALPHA EMITTING RADIOPHARMACEUTICALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY ALPHA EMITTING RADIOPHARMACEUTICALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY BETA EMITTING RADIOPHARMACEUTICALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY BETA EMITTING RADIOPHARMACEUTICALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY BETA EMITTING RADIOPHARMACEUTICALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY BETA EMITTING RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY I-131 BASED THERAPIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY I-131 BASED THERAPIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY I-131 BASED THERAPIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY LU-177 BASED THERAPIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY LU-177 BASED THERAPIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY LU-177 BASED THERAPIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY Y-90 BASED THERAPIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY Y-90 BASED THERAPIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY Y-90 BASED THERAPIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY ISOTOPE TYPE, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY CYCLOTRON PRODUCED ISOTOPES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY CYCLOTRON PRODUCED ISOTOPES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY CYCLOTRON PRODUCED ISOTOPES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY CYCLOTRON PRODUCED ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY C-11, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY C-11, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY C-11, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY F-18, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY F-18, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY F-18, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY GENERATOR BASED ISOTOPES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY GENERATOR BASED ISOTOPES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY GENERATOR BASED ISOTOPES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY GENERATOR BASED ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY GE-68 GA-68 GENERATORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY GE-68 GA-68 GENERATORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY GE-68 GA-68 GENERATORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY MO-99 TC-99M GENERATORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY MO-99 TC-99M GENERATORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY MO-99 TC-99M GENERATORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY BONE IMAGING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY BONE IMAGING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY BONE IMAGING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY CARDIOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY CARDIOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY CARDIOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY INFLAMMATION IMAGING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY INFLAMMATION IMAGING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY INFLAMMATION IMAGING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY NEUROLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY NEUROLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY NEUROLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY AMBULATORY CARE FACILITIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY AMBULATORY CARE FACILITIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY AMBULATORY CARE FACILITIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY DIAGNOSTIC IMAGING CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY DIAGNOSTIC IMAGING CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY DIAGNOSTIC IMAGING CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY HOSPITAL RADIOLOGY DEPARTMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY HOSPITAL RADIOLOGY DEPARTMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY HOSPITAL RADIOLOGY DEPARTMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY RESEARCH ORGANIZATIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY RESEARCH ORGANIZATIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY RESEARCH ORGANIZATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY OFFLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY OFFLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY OFFLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY ONLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY ONLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY ONLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 105. AMERICAS NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 106. AMERICAS NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 107. AMERICAS NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY DIAGNOSTIC RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 108. AMERICAS NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY PET RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 109. AMERICAS NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY SPECT RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 110. AMERICAS NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 111. AMERICAS NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY BETA EMITTING RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 112. AMERICAS NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY ISOTOPE TYPE, 2018-2032 (USD MILLION)
  • TABLE 113. AMERICAS NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY CYCLOTRON PRODUCED ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 114. AMERICAS NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY GENERATOR BASED ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 115. AMERICAS NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 116. AMERICAS NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 117. AMERICAS NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 118. NORTH AMERICA NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 119. NORTH AMERICA NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 120. NORTH AMERICA NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY DIAGNOSTIC RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 121. NORTH AMERICA NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY PET RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 122. NORTH AMERICA NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY SPECT RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 123. NORTH AMERICA NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 124. NORTH AMERICA NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY BETA EMITTING RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 125. NORTH AMERICA NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY ISOTOPE TYPE, 2018-2032 (USD MILLION)
  • TABLE 126. NORTH AMERICA NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY CYCLOTRON PRODUCED ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 127. NORTH AMERICA NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY GENERATOR BASED ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 128. NORTH AMERICA NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 129. NORTH AMERICA NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 130. NORTH AMERICA NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 131. LATIN AMERICA NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 132. LATIN AMERICA NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 133. LATIN AMERICA NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY DIAGNOSTIC RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 134. LATIN AMERICA NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY PET RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 135. LATIN AMERICA NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY SPECT RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 136. LATIN AMERICA NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 137. LATIN AMERICA NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY BETA EMITTING RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 138. LATIN AMERICA NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY ISOTOPE TYPE, 2018-2032 (USD MILLION)
  • TABLE 139. LATIN AMERICA NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY CYCLOTRON PRODUCED ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 140. LATIN AMERICA NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY GENERATOR BASED ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 141. LATIN AMERICA NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 142. LATIN AMERICA NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 143. LATIN AMERICA NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 144. EUROPE, MIDDLE EAST & AFRICA NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPE, MIDDLE EAST & AFRICA NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPE, MIDDLE EAST & AFRICA NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY DIAGNOSTIC RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 147. EUROPE, MIDDLE EAST & AFRICA NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY PET RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPE, MIDDLE EAST & AFRICA NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY SPECT RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPE, MIDDLE EAST & AFRICA NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 150. EUROPE, MIDDLE EAST & AFRICA NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY BETA EMITTING RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPE, MIDDLE EAST & AFRICA NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY ISOTOPE TYPE, 2018-2032 (USD MILLION)
  • TABLE 152. EUROPE, MIDDLE EAST & AFRICA NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY CYCLOTRON PRODUCED ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 153. EUROPE, MIDDLE EAST & AFRICA NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY GENERATOR BASED ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 154. EUROPE, MIDDLE EAST & AFRICA NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 155. EUROPE, MIDDLE EAST & AFRICA NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 156. EUROPE, MIDDLE EAST & AFRICA NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 157. EUROPE NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 158. EUROPE NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 159. EUROPE NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY DIAGNOSTIC RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 160. EUROPE NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY PET RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 161. EUROPE NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY SPECT RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 162. EUROPE NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 163. EUROPE NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY BETA EMITTING RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 164. EUROPE NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY ISOTOPE TYPE, 2018-2032 (USD MILLION)
  • TABLE 165. EUROPE NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY CYCLOTRON PRODUCED ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPE NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY GENERATOR BASED ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 167. EUROPE NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 168. EUROPE NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 169. EUROPE NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 170. MIDDLE EAST NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 171. MIDDLE EAST NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 172. MIDDLE EAST NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY DIAGNOSTIC RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 173. MIDDLE EAST NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY PET RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 174. MIDDLE EAST NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY SPECT RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 175. MIDDLE EAST NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 176. MIDDLE EAST NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY BETA EMITTING RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 177. MIDDLE EAST NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY ISOTOPE TYPE, 2018-2032 (USD MILLION)
  • TABLE 178. MIDDLE EAST NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY CYCLOTRON PRODUCED ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 179. MIDDLE EAST NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY GENERATOR BASED ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 180. MIDDLE EAST NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 181. MIDDLE EAST NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 182. MIDDLE EAST NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 183. AFRICA NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 184. AFRICA NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 185. AFRICA NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY DIAGNOSTIC RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 186. AFRICA NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY PET RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 187. AFRICA NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY SPECT RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 188. AFRICA NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 189. AFRICA NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY BETA EMITTING RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 190. AFRICA NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY ISOTOPE TYPE, 2018-2032 (USD MILLION)
  • TABLE 191. AFRICA NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY CYCLOTRON PRODUCED ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 192. AFRICA NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY GENERATOR BASED ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 193. AFRICA NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 194. AFRICA NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 195. AFRICA NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 196. ASIA-PACIFIC NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 197. ASIA-PACIFIC NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 198. ASIA-PACIFIC NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY DIAGNOSTIC RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 199. ASIA-PACIFIC NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY PET RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 200. ASIA-PACIFIC NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY SPECT RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 201. ASIA-PACIFIC NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 202. ASIA-PACIFIC NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY BETA EMITTING RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 203. ASIA-PACIFIC NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY ISOTOPE TYPE, 2018-2032 (USD MILLION)
  • TABLE 204. ASIA-PACIFIC NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY CYCLOTRON PRODUCED ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 205. ASIA-PACIFIC NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY GENERATOR BASED ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 206. ASIA-PACIFIC NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 207. ASIA-PACIFIC NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 208. ASIA-PACIFIC NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 209. GLOBAL NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 210. ASEAN NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 211. ASEAN NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 212. ASEAN NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY DIAGNOSTIC RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 213. ASEAN NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY PET RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 214. ASEAN NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY SPECT RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 215. ASEAN NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 216. ASEAN NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY BETA EMITTING RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 217. ASEAN NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY ISOTOPE TYPE, 2018-2032 (USD MILLION)
  • TABLE 218. ASEAN NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY CYCLOTRON PRODUCED ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 219. ASEAN NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY GENERATOR BASED ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 220. ASEAN NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 221. ASEAN NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 222. ASEAN NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 223. GCC NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 224. GCC NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 225. GCC NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY DIAGNOSTIC RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 226. GCC NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY PET RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 227. GCC NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY SPECT RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 228. GCC NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 229. GCC NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY BETA EMITTING RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 230. GCC NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY ISOTOPE TYPE, 2018-2032 (USD MILLION)
  • TABLE 231. GCC NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY CYCLOTRON PRODUCED ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 232. GCC NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY GENERATOR BASED ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 233. GCC NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 234. GCC NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 235. GCC NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 236. EUROPEAN UNION NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 237. EUROPEAN UNION NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 238. EUROPEAN UNION NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY DIAGNOSTIC RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 239. EUROPEAN UNION NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY PET RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 240. EUROPEAN UNION NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY SPECT RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 241. EUROPEAN UNION NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 242. EUROPEAN UNION NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY BETA EMITTING RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 243. EUROPEAN UNION NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY ISOTOPE TYPE, 2018-2032 (USD MILLION)
  • TABLE 244. EUROPEAN UNION NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY CYCLOTRON PRODUCED ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 245. EUROPEAN UNION NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY GENERATOR BASED ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 246. EUROPEAN UNION NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 247. EUROPEAN UNION NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 248. EUROPEAN UNION NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 249. BRICS NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 250. BRICS NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 251. BRICS NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY DIAGNOSTIC RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 252. BRICS NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY PET RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 253. BRICS NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY SPECT RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 254. BRICS NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 255. BRICS NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY BETA EMITTING RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 256. BRICS NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY ISOTOPE TYPE, 2018-2032 (USD MILLION)
  • TABLE 257. BRICS NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY CYCLOTRON PRODUCED ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 258. BRICS NUCLEAR MEDICINE & RADIOPHARMACEUTICALS MARKET SIZE, BY GENERATOR BASED ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 259. BRICS NUCLEAR MEDICINE & RADIOPHARMACEUTICA